We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Thromboelastometry Analysis Assessed for Thrombocytopenic Dengue Patients

By LabMedica International staff writers
Posted on 01 Feb 2017
Dengue virus infection (DVI) is a prevalent and potentially fatal viral disease associated with coagulopathy. More...
Dengue hemorrhagic fever (DHF) represents a severe clinical presentation of DVI and is characterized by the presence of varying degrees of hemostatic disorders.

Rotational thromboelastometry is a point of care test that promptly provides within 5 to 30 minutes information about the dynamics of clot formation, stabilization and dissolution, reflecting the in vivo hemostasis at the bedside.

Physicians at the Hospital Israelita Albert Einstein conducted a cross-sectional study during a DVI outbreak in São Paulo, Brazil, between April 6 and May 5, 2015. Patients with at least 24 hours of fever (axillary temperature greater than 37.8 °C), in addition to a positive dengue virus (DV) specific immunoglobulin IgM/IgG or non-structural protein-1 (NS1) antigen rapid test and platelet count less than 100 × 109/L were consecutively included in this study.

Rotational Thromboelastometry and the conventional coagulation tests prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), thrombin time (TT), platelet count and fibrinogen levels were performed in 53 patients with DVI and thrombocytopenia. Measurement of coagulation in ROTEM was performed after the vertical immersion of a plastic pin into the blood sample. The pin rotates slowly backwards and forwards through an angle of 4.75°. By generation of the first fibrin filaments between the pin and the wall of the test cup, the rotational range of the pin is reduced. The increased restriction of the pin’s movement is transferred to a graphical display, a plot that shows changes in the viscoelastic properties of the clot over time.

The team found that despite a median interquartile range (IQR) platelet count of 77 (63–88) × 109/L in DVI patients, conventional coagulation tests and plasma fibrinogen levels were within the normal range. Subjects demonstrated hypercoagulability in 71.7% (38/53) in intrinsically activated thromboelastometry test (INTEM) and 54.7% (29/53) in extrinsically activated thromboelastometry test (EXTEM) in DVI patients. Fibrin-based thromboelastometry test (FIBTEM) analyses detected only 5.7% (3/53) with hypocoagulability among this population. The median (IQR) clotting time (CT), clot formation time (CFT) and maximum clot firmness (MCF) on INTEM were, respectively, 177 (160–207) seconds, 144 (108–178) seconds and 48 (42–52) mm. On EXTEM, median (IQR) CT, CFT and MCF were, respectively, 69 (65–78) seconds, 148 (126–198) seconds and 49 (44–55) mm.

The authors concluded that thromboelastometry impairment is highly prevalent in DVI patients with thrombocytopenia, particularly in INTEM and EXTEM analyses, while standard coagulation tests are normal in this setting, but clinical implications remain to be established. The study was published on January 19, 2017, in the journal BMC Infectious Diseases.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.